Inclisiran (Leqvio) for Women Over 65: What to Know Before Your First Injection

Why Cardiovascular Risk Changes So Dramatically After Menopause

Cardiovascular disease kills more women over 65 than any other condition. The reason LDL management becomes so urgent after menopause is not simply aging. It is biology.

Estrogen supports several mechanisms that keep LDL in check: it upregulates hepatic LDL-receptor expression, promotes HDL particle maturation, and has direct anti-inflammatory effects on arterial walls. When ovarian estrogen production falls at menopause, LDL-C typically rises by 10 to 14 mg/dL within the first year after the final menstrual period. That shift compounds over years and explains why women who had lower cardiovascular event rates than men during their reproductive years catch up rapidly in their late 50s and overtake men in absolute event burden by their mid-70s.

Cardiovascular disease accounts for 1 in 3 deaths among American women, and the majority of those deaths occur after age 65. Treating LDL aggressively in this window is not optional for high-risk women. It is the single intervention with the most durable trial evidence behind it.

How Statins Fall Short in Older Women

Statins remain first-line therapy, and most women over 65 with established atherosclerotic cardiovascular disease (ASCVD) should be on one. The problem is that statin intolerance is more common in women than in men. Women represent about 60 percent of patients who discontinue statins due to myalgia. Age compounds this: older muscle is more vulnerable to statin-related myopathy, and polypharmacy in women over 65 increases cytochrome P450 interaction risk with lipophilic statins.

Even among women who tolerate statins well, high-intensity statin therapy (rosuvastatin 20-40 mg, atorvastatin 40-80 mg) reduces LDL by roughly 50 percent at most. A woman entering menopause with an LDL of 160 mg/dL may still sit at 80 mg/dL on maximal statin therapy, well above the <55 mg/dL target recommended by the 2022 ACC/AHA guidelines for very-high-risk patients. Inclisiran fills that gap.

The PCSK9 Pathway and Why It Matters for Postmenopausal Women

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that degrades LDL receptors on hepatocytes. More PCSK9 means fewer receptors, which means LDL stays in circulation instead of being cleared. Estrogen suppresses PCSK9 expression. After menopause, PCSK9 activity increases, which is one molecular reason LDL rises at menopause independently of diet or lifestyle.

Inclisiran is a small-interfering RNA (siRNA) that silences PCSK9 messenger RNA inside liver cells. It does not circulate systemically the way monoclonal antibodies (evolocumab, alirocumab) do. It goes straight to the hepatocyte, degrades the PCSK9 transcript before the protein is even made, and then is itself cleared. That intracellular mechanism is why a single 284 mg dose can suppress PCSK9 for six months.

What the Clinical Trials Show for Older Women

The three key phase 3 ORION trials (ORION-9, ORION-10, ORION-11) enrolled a combined 3,457 participants and showed consistent LDL reductions of 44 to 52 percent from baseline compared with placebo at day 510. These trials did not pre-specify a geriatric subgroup analysis, which is an important evidence gap. Age subgroup data exist but were not powered for statistical independence.

What the Age Subgroup Data Show

In a pooled post-hoc analysis of the ORION-10 and ORION-11 trials, efficacy was consistent across age tertiles. Participants aged 65 and older showed LDL reductions numerically similar to those under 65, with no statistically significant interaction between age and treatment effect. The ORION-10 trial, published in the New England Journal of Medicine in 2020, enrolled 1,561 participants with a mean age of 66 years, meaning the dataset has real geriatric representation even if it was not analyzed as such.

The ORION-11 trial, which enrolled European patients with ASCVD or high cardiovascular risk, had a median participant age of 66.5 years, with the 65-and-older group constituting approximately 40 percent of the enrolled population. LDL reduction in women in that trial was approximately 48 percent from baseline, consistent with the overall population.

What Is Still Missing: The Women-Specific Evidence Gap

The ORION trials enrolled roughly 40 percent women overall, which is better than many cardiovascular trials but still leaves sex-specific subgroup analyses underpowered. Women have historically been underrepresented in cardiovascular outcomes trials, and inclisiran is no exception. The available data support using inclisiran in postmenopausal women based on consistent efficacy signals, but direct trial data in postmenopausal women as a defined subgroup do not exist. What we have is extrapolated from mixed-sex cohorts. Prescribers and patients should understand that distinction.

The ORION-4 trial, a 15,000-person outcomes study expected to read out around 2026, will provide the first direct evidence on whether inclisiran reduces cardiovascular events (not just LDL) in older adults. Women make up a meaningful portion of that enrollment.

Dosing and Administration in Women Over 65

The approved dose of inclisiran is 284 mg subcutaneously at baseline, again at three months, then every six months. That dosing schedule does not change based on age. There is no geriatric-specific dose reduction.

Site and Technique Considerations for Older Women

Inclisiran is administered in a clinician's office, not self-injected at home. The injection sites are the abdomen (avoiding the periumbilical 2-inch zone), the upper arm, or the thigh. For women over 65 with reduced subcutaneous fat or fragile skin, the clinician should rotate sites carefully. Injection site reactions (redness, pain, bruising) occurred in 8.2 percent of inclisiran-treated patients vs. 1.8 percent on placebo in the ORION-10 and ORION-11 pools.

Renal and Hepatic Considerations Common in Older Women

Chronic kidney disease (CKD) prevalence increases with age and is slightly higher in women than men after age 65. The FDA label states no dose adjustment is needed for mild-to-moderate renal impairment (eGFR 30-59 mL/min/1.73m2). For severe renal impairment (eGFR <30) or end-stage renal disease, data are limited and the label notes that inclisiran has not been studied in these groups. Use in that population requires an individualized risk-benefit conversation.

Mild-to-moderate hepatic impairment also requires no dose adjustment. Severe hepatic impairment has not been studied.

Drug Interactions and Polypharmacy in the 65-Plus Woman

Older women carry a high polypharmacy burden. A 2019 analysis found that women 65 and older take an average of 5.5 prescription medications per day. Inclisiran's safety profile in this context is one of its advantages.

Because inclisiran acts inside hepatocytes via RNA interference and is not metabolized by CYP450 enzymes, it has no known pharmacokinetic drug-drug interactions. It does not interact with warfarin, levothyroxine, amlodipine, or the other drugs commonly used in this age group. This is a meaningful practical advantage over statin combinations or fibrates, which carry real interaction risks.

There is one indirect concern: if a woman is on a P-glycoprotein substrate with a narrow therapeutic index (digoxin, for example), inclisiran does not itself interact, but monitoring standard lipid-lowering regimen adjustments remains important as you optimize the overall cardiovascular drug burden.

Conditions Relevant to Women Over 65 That Intersect With Inclisiran Use

Hypothyroidism and LDL

Hypothyroidism, including postpartum thyroiditis that becomes permanent, is far more common in women than men and increases with age. Untreated or undertreated hypothyroidism raises LDL substantially. Before prescribing inclisiran, confirm that TSH is within goal range, because normalizing thyroid function may reduce LDL enough to change the treatment decision.

Type 2 Diabetes and Metabolic Disease

Women with PCOS who carry that diagnosis into their 50s and 60s have elevated lifetime cardiovascular risk driven by insulin resistance and dyslipidemia. Inclisiran addresses the LDL component but does not affect triglycerides or HDL meaningfully. Women with diabetic dyslipidemia may need combination therapy to address the full lipid panel.

Osteoporosis and Statin Myopathy

There is no direct interaction between inclisiran and bone metabolism. For women who stopped statins because of myopathy and who also have osteoporosis, inclisiran represents a way to address LDL without worsening musculoskeletal symptoms. That is a clinically meaningful benefit for a subset of women over 65 who have felt forced to choose between cardiovascular and bone-related care.

Female Pattern Hair Loss and Hormonal Acne

These conditions are not directly relevant to inclisiran therapy, but they often bring postmenopausal women into conversations about hormonal and metabolic health. If a woman is discussing hair thinning or scalp changes with her clinician, it is worth checking her full metabolic and lipid panel at the same visit, since dyslipidemia and insulin resistance often co-exist with androgenic conditions even after menopause.

Who This Is Right For, and Who Should Wait

This framework helps organize the decision by life stage and clinical profile for women over 65.

Strong candidates for inclisiran:

• Postmenopausal women with established ASCVD (prior MI, stroke, or peripheral arterial disease) whose LDL remains above 55 mg/dL despite maximally tolerated statin plus ezetimibe
• Women with heterozygous familial hypercholesterolemia (HeFH) who cannot reach LDL targets on statin alone, regardless of cardiovascular event history
• Women with documented statin intolerance (confirmed by rechallenge or creatine kinase elevation) who need meaningful additional LDL lowering
• Women who have difficulty with daily oral medication adherence and would benefit from a twice-yearly injection over a daily pill

Women who should pause and discuss first:

• Women with severe CKD (eGFR <30) or on dialysis, where trial data are absent
• Women on digoxin or other narrow-therapeutic-index drugs who need careful monitoring of the overall regimen context
• Women whose LDL is not at therapeutic goal because of undertreated hypothyroidism or uncontrolled diabetes; address those first before adding inclisiran
• Women whose LDL is moderately elevated but who do not meet the approved indication (ASCVD or HeFH); inclisiran is not approved for primary prevention and off-label use in lower-risk women is not supported by outcomes data

Women for whom inclisiran is generally not appropriate:

• Women who do not yet have ASCVD and whose 10-year cardiovascular risk does not place them in a high-risk category
• Women in whom cost is a significant barrier and who have not yet optimized ezetimibe, a generic that costs under $10 per month and adds approximately 20 percent LDL reduction on top of a statin

Pregnancy, Lactation, and Contraception

Inclisiran is contraindicated in pregnancy. PCSK9 is expressed in fetal tissue, and the long-term silencing of PCSK9 mRNA in a developing fetus carries unknown but theoretically significant developmental risks. The FDA label carries a specific pregnancy warning based on animal reproduction data showing fetal harm at doses below the human therapeutic dose.

For the vast majority of women receiving inclisiran over 65, pregnancy is not a consideration. Menopause, by definition, marks the end of the reproductive window. However, early postmenopause (ages 50-55) presents a gray zone. Women in perimenopause who have not yet had 12 consecutive months without a period should use reliable contraception during inclisiran therapy, and inclisiran should not be started in any woman who could be pregnant or who is attempting conception.

Lactation data do not exist. Because inclisiran targets hepatocytes via a mechanism that involves systemic distribution before hepatic uptake, there is theoretical concern about transfer into breast milk, though the drug's large molecular size (a modified siRNA duplex) makes meaningful oral bioavailability in a nursing infant unlikely. The FDA label advises against use during breastfeeding, and given the non-urgent nature of LDL management for most individuals, discontinuing or delaying therapy during lactation is the appropriate recommendation.

No specific contraceptive requirement is listed in the FDA label beyond the general contraindication in pregnancy. For perimenopausal women, any reliable method is acceptable.

Practical Guidance on Cost, Access, and the Patient-Assistance Field

Inclisiran's list price in the United States is approximately $3,500 to $3,600 per injection, or roughly $7,200 per year. For women on Medicare with cardiovascular disease, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D beneficiaries beginning in 2025 meaningfully changes the affordability equation.

Novartis offers a patient-assistance program (Entresto Together, which covers inclisiran as well) for uninsured and underinsured patients. Women who face insurance denial for inclisiran despite meeting the approved indication often succeed on appeal when the prescriber documents a statin trial with documented intolerance and an inadequate LDL response to maximum-dose ezetimibe.

Prior authorization requirements almost universally apply. Expect to document: current statin and dose, reason for any dose limitation, ezetimibe trial and LDL response, current LDL-C level, and diagnosis of ASCVD or HeFH.

Monitoring After Starting Inclisiran

A lipid panel should be checked approximately 60 to 90 days after the first injection to confirm LDL response, which typically reaches its nadir around day 60-90. After that, most clinicians check the lipid panel once yearly unless clinical circumstances change, since inclisiran's LDL-lowering effect is highly consistent between injections.

Liver function tests and creatine kinase do not require routine monitoring in the absence of symptoms. If a woman develops unexplained muscle pain after starting inclisiran while continuing a statin, evaluate CK and consider whether the statin dose is contributing.

Blood pressure, renal function, and thyroid status should continue to be monitored on their usual schedule as part of comprehensive cardiovascular risk management, not specifically because of inclisiran.

The ACC/AHA 2022 guidelines on nonstatin therapy in very-high-risk patients recommend reassessing LDL response and adherence to lifestyle at every follow-up visit. Inclisiran makes adherence much easier because of its twice-yearly dosing, but lifestyle, blood pressure control, smoking cessation, and glycemic management remain essential components of total cardiovascular risk reduction.

A Note on Evolocumab and Alirocumab: The Comparator Conversation

Women over 65 often ask how inclisiran compares with the two monoclonal antibody PCSK9 inhibitors, evolocumab (Repatha) and alirocumab (Praluent). All three reduce LDL by approximately 50 to 60 percent on top of statin therapy. The key differences:

Evolocumab and alirocumab are self-injected at home every two weeks or monthly. Inclisiran is injected in-office twice yearly. For women who have arthritis, visual impairment, or who live alone and find self-injection difficult, inclisiran's in-office administration is a genuine practical advantage.

The monoclonal antibodies have published hard cardiovascular outcomes data. FOURIER (evolocumab) showed a 15 percent relative risk reduction in major cardiovascular events over a median of 2.2 years. ODYSSEY OUTCOMES (alirocumab) showed a 15 percent relative risk reduction in major adverse cardiovascular events over a median of 2.8 years. Inclisiran does not yet have comparable outcomes data; ORION-4 is expected to fill that gap.

For a woman over 65 who needs the reassurance of outcomes trial data before committing to a new therapy class, one of the monoclonal antibodies may be a more comfortable choice today. For a woman who prioritizes simplicity and twice-yearly in-office dosing, inclisiran is a reasonable and well-supported alternative.

As one guideline statement from The Menopause Society's 2022 position statement on cardiovascular disease in menopausal women notes: "Aggressive LDL lowering remains one of the most evidence-supported interventions for reducing cardiovascular events in postmenopausal women with established disease."